Slow-released preparation containing hydrochlorothiazide and clonidine hydrochloride and its preparing method
A technology of clonidine hydrochloride and hydrochlorothiazide, which is applied to medical preparations containing active ingredients, medical preparations with non-active ingredients, and pharmaceutical formulas, etc. It can solve the problems of short duration of drug effects, easy to forget to take and miss doses, and blood drug concentration. Low-level problems, to achieve stable blood drug concentration in the body, reduce the number of administrations, and reduce the effects of toxic and side effects
- Summary
- Abstract
- Description
- Claims
- Application Information
AI Technical Summary
Problems solved by technology
Method used
Image
Examples
Embodiment 1
[0033] The following is the amount used in 1000 pieces
[0034] a. Hydrochlorothiazide immediate-release small tablets
[0035] Component Amount (g)
[0036] Hydrochlorothiazide 6
[0037] Microcrystalline Cellulose 10
[0038] Lactose 12.95
[0039] Crospovidone 0.9
[0040] Magnesium stearate 0.15
[0041] b. Hydrochlorothiazide extended-release small tablets
[0042] Component Amount (g)
[0043] Hydrochlorothiazide 31.5
[0044] Hydroxypropyl methylcellulose 12.5
[0045] Kabob 2
[0046] Lactose 8.725
[0047] Magnesium stearate 0.275
[0048] c. Clonidine Hydrochloride Sustained Release Small Tablets
[0049] Component Dosage
[0050] Clonidine hydrochloride 0.1125
[0051] Hydroxypropyl methylcellulose 25
[0052] Carbopol 2.5
[0053] Lactose 22.1375
[0054] Magnesium stearate 0.25
[0055] The preparation process is as follows:
[0056]The raw and auxiliary materials are crushed and sieved, mixed according to the above prescription amount, and then...
Embodiment 2
[0058] The consumption of present embodiment is the amount used by 1000
[0059] a. Hydrochlorothiazide immediate-release small tablets
[0060] Component Dosage
[0061] Hydrochlorothiazide 6
[0062] Microcrystalline Cellulose 10
[0063] Lactose 12.95
[0064] Crospovidone 0.9
[0065] Magnesium stearate 0.15
[0066] b. Hydrochlorothiazide extended-release small tablets
[0067] Component Amount (g)
[0068] Hydrochlorothiazide 31.5
[0069] Hydroxypropyl methylcellulose K100 10.2
[0070] Kabob 9.6
[0071] Lactose 19.2
[0072] Magnesium stearate 0.3
[0073] c. Clonidine Hydrochloride Sustained Release Small Tablets
[0074] Component Dosage
[0075] Clonidine hydrochloride 0.1125
[0076] Hydroxypropyl methylcellulose K100 30
[0077] Kabob 9
[0078] Lactose 10.6375
[0079] Magnesium stearate 0.25
[0080] The preparation method is the same as in Example 1.
Embodiment 3
[0082] The consumption of present embodiment is the amount used by 1000
[0083] a. Hydrochlorothiazide immediate-release small tablets
[0084] Component Dosage
[0085] Hydrochlorothiazide 6
[0086] Microcrystalline Cellulose 10
[0087] Lactose 12.95
[0088] Crospovidone 0.9
[0089] Magnesium stearate 0.15
[0090] b. Hydrochlorothiazide extended-release small tablets
[0091] Component Dosage
[0092] Hydrochlorothiazide 31.5
[0093] Hydroxypropyl methylcellulose K15 7.8
[0094] Carbopol 1.2
[0095] Lactose 19.2
[0096] Magnesium stearate 0.3
[0097] c. Clonidine Hydrochloride Sustained Release Small Tablets
[0098] Component Dosage
[0099] Clonidine hydrochloride 0.1125
[0100] Hydroxypropyl Methyl Cellulose K15 36
[0101] Kabob 21
[0102] Lactose 2.5875
[0103] Magnesium stearate 0.3
[0104] The preparation method is the same as in Example 1.
PUM
Abstract
Description
Claims
Application Information
- R&D Engineer
- R&D Manager
- IP Professional
- Industry Leading Data Capabilities
- Powerful AI technology
- Patent DNA Extraction
Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.
© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com